EndoDirect - Endocrinologia e Metabologia

Neste FD vamos falar sobre a aprovação da combinação icodeca com semaglutida no tratamento de pacientes diabéticos tipo 2 no Brasil.
Siga @endodirect e acesse: endodirect.com.br

Referencias:
Mathieu C, Giorgino F, Kim SG, et al. Once-weekly IcoSema versus once-weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13(7):568-79. doi:10.1016/S2213-8587(25)00096-8Lingvay I, Benamar M, Chen L, et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. 2025;68(4):739-51. doi:10.1007/s00125-024-06348-5Billings LK, Andreozzi F, Frederiksen M, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025;13(7):556-67. doi:10.1016/S2213-8587(25)00052-XJi L, Benamar M, Mohan V, et al. Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial. Lancet Diabetes Endocrinol. 2026;14(10):831-40. doi:10.1016/S2213-8587(26)00136-1

Neste FD vamos discutir sobre a recente aprovãção da ANVISA da medicação palopegteriparatida no tratamento de pacientes com hipoparatireoidismo crônico.
Acesse: endodirect.com.br
Referencias
Khan AA et al. JBMR 2023;
Clarke BL et al. JCEM 2025;
Rejnmark L et al. JBMR 2026;
Khan AA et al. JCEM 2022
Khan AA et al. JBMR 2022

Neste FD vamos falar brevemente sobre a hiperferritinemia dismetabólica e a Síndrome de Sobrecarga de Ferro Dismetabólica.
Siga: @endodirect e acesse: endodirect.com.br
Referencias utilizadas:
TOFANO, R. J. et al. Association of metabolic syndrome and hyperferritinemia in patients at cardiovascular risk.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, [s. l.], v. 13, p. 3239-3248, 2020
LAINÉ, F. et al. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: a randomized controlled study in 274 patients. Hepatology, Baltimore, v. 65, n. 2, p. 465-474, 2017. DEUGNIER, Y.; BARDOU-JACQUET, É.; LAINÉ, F. Dysmetabolic iron overload syndrome (DIOS). Presse Médicale, Paris, v. 46, n. 12, pt. 2, p. e306-e311,2017.

Neste FD abordamos resumidamente os principais pontos do guideline de tratamento do diabetes tipo 2 da Sociedade Brasileira de Diabetes atualizado em agosto de 2026.
Siga @endodirect
Acesse: endodirect.com.br

Neste FD vamos falar sobre a mudança do nome de Síndrome dos Ovários Policísticos para Síndrome Ovariana Metabólica Poliendócrina, sobre o histórico de classificação e sobre os fenótipos da doença.
Acesse a plataforma mais completa em endocrinologia: endodirect.com.br
Referencias:
Teede HJ, Bahri Khomami M, Morman R, Laven JSE, Joham AE, Costello MF, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026
Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023Daan NMP, Louwers YV, Koster MPH, Eijkemans MJC, de Rijke YB, Lentjes EWG, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014